GH Research PLC (NASDAQ:GHRS – Free Report) – Research analysts at HC Wainwright raised their FY2023 EPS estimates for GH Research in a report released on Tuesday, November 14th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($0.65) for the year, up from their previous forecast of ($0.69). HC Wainwright has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for GH Research’s current full-year earnings is ($0.76) per share. HC Wainwright also issued estimates for GH Research’s Q4 2023 earnings at ($0.19) EPS, FY2024 earnings at ($0.79) EPS, FY2025 earnings at ($0.84) EPS and FY2026 earnings at ($1.05) EPS.
GH Research (NASDAQ:GHRS – Get Free Report) last released its quarterly earnings data on Wednesday, August 23rd. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.06.
GH Research Stock Performance
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of the business. RTW Investments LP grew its holdings in shares of GH Research by 53.4% during the third quarter. RTW Investments LP now owns 3,327,129 shares of the company’s stock worth $33,438,000 after buying an additional 1,158,172 shares during the last quarter. Citadel Advisors LLC increased its holdings in shares of GH Research by 2.2% in the second quarter. Citadel Advisors LLC now owns 1,303,470 shares of the company’s stock valued at $13,009,000 after purchasing an additional 27,738 shares during the period. Lynx1 Capital Management LP raised its position in GH Research by 13.8% during the 3rd quarter. Lynx1 Capital Management LP now owns 1,103,178 shares of the company’s stock worth $11,087,000 after buying an additional 133,804 shares during the last quarter. Morgan Stanley lifted its stake in shares of GH Research by 7.1% in the 4th quarter. Morgan Stanley now owns 524,115 shares of the company’s stock worth $5,094,000 after acquiring an additional 34,779 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in GH Research by 16.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 92,784 shares of the company’s stock valued at $932,000 after purchasing an additional 12,911 shares during the period.
GH Research Company Profile
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies to treat psychiatric and neurological disorders. The company develops 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable mebufotenin product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD.
- Five stocks we like better than GH Research
- Most Volatile Stocks, What Investors Need to Know
- Buffett’s latest portfolio additions, trims, and cuts in Q3
- How to Invest in Communication Stocks
- 5 reasons TJX Companies will hit new highs in 2024
- There Are Different Types of Stock To Invest In
- Game-changing news for Ambarella puts the market in reversal
Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.